Furthermore, patients with ovarian tumors with high DOT1L expression had shorter progression-free survival (PFS) and (OS) than patients with ovarian tumors with low DOT1L expression (Fig. 1D, E). The gene discussed is DOT1L; the disease is ovarian neoplasm.